MiR‐199a‐5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer

Cancer cells possess a unique metabolic phenotype that allows them to preferentially utilize glucose through aerobic glycolysis. This phenomenon is referred to as the “Warburg effect.” Accumulating evidence suggests that microRNAs (miRNAs), a class of small noncoding regulatory RNAs, interact with oncogenes/tumor suppressors and induce such metabolic reprograming in cancer cells. To systematically study the metabolic roles of miRNAs in cancer cells, we developed a gain‐of‐function miRNA screen in HeLa cells. Subsequent investigation of the characterized miRNAs indicated that miR‐199a‐5p acts as a suppressor for glucose metabolism. Furthermore, miR‐199a‐5p is often down‐regulated in human liver cancer, and its low expression level was correlated with a low survival rate, large tumor size, poor tumor differentiation status, high tumor‐node‐metastasis stage and the presence of tumor thrombus of patients. MicroRNA‐199a‐5p directly targets the 3′‐untranslated region of hexokinase 2 (HK2), an enzyme that catalyzes the irreversible first step of glycolysis, thereby suppressing glucose consumption, lactate production, cellular glucose‐6‐phosphate and adenosine triphosphate levels, cell proliferation, and tumorigenesis of liver cancer cells. Moreover, HK2 is frequently up‐regulated in liver cancer tissues and associated with poor patient outcomes. The up‐regulation of hypoxia‐inducible factor‐1α under hypoxic conditions suppresses the expression of miR‐199a‐5p and promotes glycolysis, whereas reintroduction of miR‐199a‐5p interferes with the expression of HK2, abrogating hypoxia‐enhanced glycolysis. Conclusion: miR‐199a‐5p/HK2 reprograms the metabolic process in liver cancer cells and provides potential prognostic predictors for liver cancer patients. (Hepatology 2015;62:1132‐1144)

[1]  A. Sood,et al.  Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis , 2014, Proceedings of the National Academy of Sciences.

[2]  Bin Liu,et al.  Hypoxia and hypoxia-inducible factor 1 repress SEMA4B expression to promote non-small cell lung cancer invasion , 2014, Tumor Biology.

[3]  Fan Yang,et al.  Reciprocal regulation of HIF-1α and lincRNA-p21 modulates the Warburg effect. , 2014, Molecular cell.

[4]  Abhishek K. Jha,et al.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. , 2013, Cancer cell.

[5]  Jie Sun,et al.  MicroRNAs in Hepatocellular Carcinoma: Regulation, Function, and Clinical Implications , 2013, TheScientificWorldJournal.

[6]  L. Zentilin,et al.  Functional screening identifies miRNAs inducing cardiac regeneration , 2012, Nature.

[7]  B. Hernandez,et al.  Choline Kinase Alpha and Hexokinase-2 Protein Expression in Hepatocellular Carcinoma: Association with Survival , 2012, PloS one.

[8]  P. Gao,et al.  MicroRNAs and the Warburg Effect: new players in an old arena. , 2012, Current gene therapy.

[9]  A. Krogh,et al.  MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells , 2012, BMC Cancer.

[10]  H. Ji,et al.  MicroRNA-143 (miR-143) Regulates Cancer Glycolysis via Targeting Hexokinase 2 Gene* , 2012, The Journal of Biological Chemistry.

[11]  Yong Li,et al.  A novel miR‐155/miR‐143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells , 2012, The EMBO journal.

[12]  Stephanie Roessler,et al.  Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. , 2012, Gastroenterology.

[13]  A. Näär,et al.  MicroRNAs in metabolism and metabolic disorders , 2012, Nature Reviews Molecular Cell Biology.

[14]  Franziska Hirschhaeuser,et al.  Lactate: a metabolic key player in cancer. , 2011, Cancer research.

[15]  Y. Okamoto,et al.  Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. , 2011, International journal of oncology.

[16]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[17]  Li Lin,et al.  Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. , 2011, Cancer cell.

[18]  T. Kawai,et al.  Long-term experience with liver transplantation for hepatocellular carcinoma , 2011, Journal of Gastroenterology.

[19]  Joydeep Mukherjee,et al.  Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme , 2011, The Journal of experimental medicine.

[20]  Thomas D. Schmittgen,et al.  miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. , 2010, Biochemical and biophysical research communications.

[21]  Qing Jing,et al.  MicroRNAs are dynamically regulated in hypertrophic hearts, and miR‐199a is essential for the maintenance of cell size in cardiomyocytes , 2010, Journal of cellular physiology.

[22]  V. Kalra,et al.  Hypoxia-Mediated Expression of 5-Lipoxygenase–Activating Protein Involves HIF-1α and NF-κB and MicroRNAs 135a and 199a-5p , 2010, The Journal of Immunology.

[23]  Chi V Dang,et al.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. , 2010, Cancer research.

[24]  Joseph Loscalzo,et al.  MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. , 2009, Cell metabolism.

[25]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[26]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[27]  Saroj P. Mathupala,et al.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. , 2009, Seminars in cancer biology.

[28]  N. Hay,et al.  Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. , 2009, Seminars in cancer biology.

[29]  Yvonne Tay,et al.  MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation , 2008, Nature.

[30]  Jianren Gu,et al.  Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma , 2008, International journal of cancer.

[31]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[32]  H. Eltzschig,et al.  HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. , 2008, Blood.

[33]  C. Croce,et al.  MiR-15a and miR-16-1 cluster functions in human leukemia , 2008, Proceedings of the National Academy of Sciences.

[34]  Krista A. Zanetti,et al.  Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.

[35]  Thomas D. Schmittgen,et al.  Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival , 2008, Clinical Cancer Research.

[36]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[37]  Ko-Fan Chen,et al.  Transcriptional repression of human cad gene by hypoxia inducible factor-1α , 2005, Nucleic acids research.

[38]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[39]  E. Rofstad,et al.  High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. , 2000, Cancer research.

[40]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[41]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[42]  S. Jacob,et al.  Regulation of glucose metabolism in hepatocarcinogenesis by microRNAs. , 2014, Gene expression.

[43]  S. Arii,et al.  Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. , 2004, Journal of hepatology.

[44]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[45]  Saroj P. Mathupala,et al.  Aberrant Glycolytic Metabolism of Cancer Cells: A Remarkable Coordination of Genetic, Transcriptional, Post-translational, and Mutational Events That Lead to a Critical Role for Type II Hexokinase , 1997, Journal of bioenergetics and biomembranes.